SIGA · Siga Technologies Inc
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Equibles Research
All SIGA researchGuidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| BARDA 19C contract funding added to support manufacturing activities | $14M | April 2025 | — |
| International Procurement Order for Oral TPOXX | $13M | January 2026 | — |
| IV TPOXX procurement order from the U.S. Government under the 19C BARDA contract | $26M | March 2025 | — |
| IV TPOXX revenues from U.S. Strategic National Stockpile | $26M | 2025 | — |
| Oral TPOXX deliveries to a repeating international customer | $6M | 2025 | — |
| Oral TPOXX revenues from U.S. Strategic National Stockpile | $53M | 2025 | — |
| Pre-tax operating income | $24M | 2025 | — |
| Product sales | $88M | Year Ended December 31, 2025 | — |
| U.S. Government funding for development activities | $27M | 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SIGA
this stock
Siga Technologies Inc
|
$246.73M | -43.7% | -31.8% | 12.3 | 4.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$54.77B | +10.0% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.12B | +3.1% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.48B | -0.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SIGA | -4.2% | -20.2% | -48.2% | -5.5% | -43.7% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -2.6% | -20.5% | -56.0% | -5.0% | -52.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.